CDMO vs. UROV, GTHX, RIGL, PAND, MIRM, JANX, AMRX, DCPH, MRVI, and PTGX
Should you be buying Avid Bioservices stock or one of its competitors? The main competitors of Avid Bioservices include Urovant Sciences (UROV), G1 Therapeutics (GTHX), Rigel Pharmaceuticals (RIGL), Pandion Therapeutics (PAND), Mirum Pharmaceuticals (MIRM), Janux Therapeutics (JANX), Amneal Pharmaceuticals (AMRX), Deciphera Pharmaceuticals (DCPH), Maravai LifeSciences (MRVI), and Protagonist Therapeutics (PTGX). These companies are all part of the "medical" sector.
Urovant Sciences (NASDAQ:UROV) and Avid Bioservices (NASDAQ:CDMO) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, media sentiment, community ranking, profitability, earnings, dividends and risk.
Urovant Sciences has a beta of 2.36, indicating that its stock price is 136% more volatile than the S&P 500. Comparatively, Avid Bioservices has a beta of 1.36, indicating that its stock price is 36% more volatile than the S&P 500.
Avid Bioservices has higher revenue and earnings than Urovant Sciences. Avid Bioservices is trading at a lower price-to-earnings ratio than Urovant Sciences, indicating that it is currently the more affordable of the two stocks.
Urovant Sciences has a net margin of 0.00% compared to Urovant Sciences' net margin of -100.57%. Avid Bioservices' return on equity of 0.00% beat Urovant Sciences' return on equity.
18.4% of Urovant Sciences shares are held by institutional investors. Comparatively, 97.2% of Avid Bioservices shares are held by institutional investors. 2.7% of Urovant Sciences shares are held by company insiders. Comparatively, 2.4% of Avid Bioservices shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Avid Bioservices received 290 more outperform votes than Urovant Sciences when rated by MarketBeat users. Likewise, 66.55% of users gave Avid Bioservices an outperform vote while only 57.35% of users gave Urovant Sciences an outperform vote.
Avid Bioservices has a consensus target price of $12.67, suggesting a potential upside of 23.82%. Given Urovant Sciences' higher possible upside, analysts plainly believe Avid Bioservices is more favorable than Urovant Sciences.
In the previous week, Avid Bioservices had 2 more articles in the media than Urovant Sciences. MarketBeat recorded 2 mentions for Avid Bioservices and 0 mentions for Urovant Sciences. Urovant Sciences' average media sentiment score of 0.44 beat Avid Bioservices' score of 0.00 indicating that Avid Bioservices is being referred to more favorably in the news media.
Summary
Avid Bioservices beats Urovant Sciences on 11 of the 16 factors compared between the two stocks.
Get Avid Bioservices News Delivered to You Automatically
Sign up to receive the latest news and ratings for CDMO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CDMO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Avid Bioservices Competitors List
Related Companies and Tools
